Tenderwize
Retour à la recherche

Open house Nilotinib discount agreements

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jan 04, 2027 · 128 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Nilotinib, ATC L01EA03 (ausgeschlossen Nilotinib dispergiert in Apfelmus, es sei denn, der Hersteller genießt hierfür Patentschutz)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or volume data; actual discounts and market share impact unknown.

Open-house agreements automatically terminate if a competitive discount contract takes effect for the same substance.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Pharmaceutical companies can enter into non-exclusive discount agreements with AOK Bayern for Nilotinib (ATC L01EA03).
  • Exclusion: Nilotinib dispersed in applesauce unless the manufacturer holds patent protection.
Afficher le résumé complet

This is an open-house model (not a competitive tender) by AOK Bayern for non-exclusive discount agreements on Nilotinib (ATC L01EA03). Any eligible pharmaceutical company can join by submitting a signed declaration of reliability and a signed contract along with an annex listing the medicines. The agreement runs from 01.03.2025 to 28.02.2027, with possible termination with one month's notice. The open-house model is not subject to procurement law; the form is used only due to lack of a dedicated form. No estimated value is provided.

Risques

No estimated value or volume data; actual discounts and market share impact unknown.

Open-house agreements automatically terminate if a competitive discount contract takes effect for the same substance.

Exigences clés

Technical

  • Must be a pharmaceutical company.
  • Proof of authorization to sign (commercial register extract or power of attorney).

Administrative

  • Submit signed contract, signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed declaration of reliability.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Nilotinib discount agreements

Non-exclusive discount agreements for Nilotinib (ATC L01EA03), excluding Nilotinib dispersed in applesauce unless patent-protected. All interested pharmaceutical companies meeting eligibility can join. The contract is standard and non-negotiable.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Feb 2025 - Feb 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jan 05, 2027

Détails de la procédure

Date de publication
21 Jan 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
44907-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30